Roivant Sciences Hits New 52-Week High of $16.14, Up 48.87%
Roivant Sciences has reached a significant milestone by hitting a new 52-week high of USD 16.14 on October 1, 2025. This achievement marks a notable increase from its 52-week low of USD 8.73, reflecting a robust performance over the past year. The stock has demonstrated a remarkable 48.87% increase in value, significantly outperforming the S&P 500, which has seen a gain of 16.09% during the same period.As a small-cap company in the Pharmaceuticals & Biotechnology sector, Roivant Sciences has a market capitalization of USD 8,816 million. Despite being in a loss-making position, the company continues to navigate the competitive landscape of its industry. Key financial metrics include a negative return on equity of -23.18% and a debt-to-equity ratio of -1.03, indicating a unique financial structure. The price-to-book ratio stands at 2.03, further illustrating the company's valuation in the market. This recent price movement highlights Roivant Sciences' evolving position within the pharmaceuticals sector.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
